不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
条条大路通罗马？新型靶向药物时代达到治疗缓解并接受自体造血干细胞移植的复发/难治性弥漫大 B 细胞淋巴瘤患者的异质性
英文原题：Do all roads lead to Rome? The heterogeneity of relapsed/refractory diffuse large B-cell lymphoma patients who achieved therapies response and received autologous stem cell transplantation in the era of new targeted drugs.
查看英文原题
Do all roads lead to Rome? The heterogeneity of relapsed/refractory diffuse large B-cell lymphoma patients who achieved therapies response and received autologous stem cell transplantation in the era of new targeted drugs.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在这项多中心研究中，我们旨在确定在新药和嵌合抗原受体（CAR）T细胞治疗时代接受自体干细胞移植（ASCT）的复发/难治性弥漫大B细胞淋巴瘤（DLBCL）患者的预后因素。共纳入四个移植中心的82例接受ASCT的复发/难治性DLBCL患者。3年疾病进展概率、非复发死亡率（NRM）、无进展生存期（PFS）和总生存期（OS）分别为23.5%、2.8%、73.7%和91.4%。与未接受Pola-R-CHP的患者相比，ASCT前接受Pola-R-CHP的患者在ASCT后疾病进展率更高（85.7% vs. 18.4%，P = 0.034），PFS更差（0% vs. 79.9%，P < 0.001）。与未接受BTKi的患者相比，ASCT前接受BTKi的患者在ASCT后疾病进展率更高（60.0% vs. 18.2%，P = 0.025），PFS率更差（23.8% vs. 81.8%，P < 0.001）。在多因素分析中，ASCT前接受新药治疗与更高的疾病进展风险和更差的PFS独立相关。
总之，我们观察到达到治疗缓解并接受ASCT的复发/难治性DLBCL患者存在异质性，其中部分患者可能无法从ASCT中获益。
展开英文摘要原文
In this multicenter study, we aimed to identify the prognostic factors for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who received autologous stem cell transplantation (ASCT) in the era of novel agents and chimeric antigen receptor (CAR) T-cell therapy. A total of 82 relapsed/refractory DLBCL patients receiving ASCT across four transplant centers were enrolled. The 3-year probabilities of disease progression, non-relapse mortality (NRM), progression-free survival (PFS), and overall survival (OS) were 23. 5%, 2. 8%, 73. 7%, and 91. 4%, respectively. Patients who received Pola-R-CHP before ASCT had a higher disease progression rate (85. 7% vs.
18. 4%, P = 0. 034) and a poorer PFS (0% vs. 79. 9%, P < 0. 001) after ASCT compared with those who did not receive Pola-R-CHP. Patients who received BTKi before ASCT had a higher disease progression rate (60. 0% vs. 18. 2%, P = 0. 025) and a poorer PFS rate (23. 8% vs. 81. 8%, P < 0. 001) after ASCT compared with those who did not receive BTKi.
In multivariate analysis, receiving novel agents before ASCT was independently associated with a higher risk of disease progression and worse PFS. In summary, we observed the heterogeneity of relapsed/refractory DLBCL patients who achieved therapies response and received ASCT, and some of them might not benefit from ASCT.
论文信息
- 作者
- Li J、Huo W、Yang Y、Zhang C、Wang F、Lu S、Feng R、Liu Y
- 第一作者单位
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.China
- 通讯作者单位
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.China
- 文献类型
- 多中心研究 · 非美国政府资助研究
- 期刊
- Cell transplantation2025 Jan-Dec
- 原文标识
- PubMed 41399277 · DOI 10.1177/09636897251397046
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →